Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.

Time: 1:26

Lymphoma

Bertrand Coiffier, MD, PhD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Apr

Today In Oncology

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Related Videos

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Richard M. Stone, MD, on the SWOG S1117 Study

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

MIBC Pembrolizumab With Trimodal Therapy for Bladder Preservation

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age